CN113179632A - 原子量子簇的治疗用途 - Google Patents

原子量子簇的治疗用途 Download PDF

Info

Publication number
CN113179632A
CN113179632A CN201980063142.3A CN201980063142A CN113179632A CN 113179632 A CN113179632 A CN 113179632A CN 201980063142 A CN201980063142 A CN 201980063142A CN 113179632 A CN113179632 A CN 113179632A
Authority
CN
China
Prior art keywords
composition
aqcs
cancer
cells
metal atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980063142.3A
Other languages
English (en)
Chinese (zh)
Inventor
D·布塞塔费尔南德斯
F·多明格斯普恩特
M·A·罗培斯昆特拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidade de Santiago de Compostela
Nanogap Sub NM Powder SA
Original Assignee
Universidade de Santiago de Compostela
Nanogap Sub NM Powder SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade de Santiago de Compostela, Nanogap Sub NM Powder SA filed Critical Universidade de Santiago de Compostela
Priority to CN202510224683.7A priority Critical patent/CN120053481A/zh
Publication of CN113179632A publication Critical patent/CN113179632A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/28—Mercury; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/05—Metallic powder characterised by the size or surface area of the particles
    • B22F1/054—Nanosized particles
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22C—ALLOYS
    • C22C5/00—Alloys based on noble metals
    • C22C5/06—Alloys based on silver
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25C—PROCESSES FOR THE ELECTROLYTIC PRODUCTION, RECOVERY OR REFINING OF METALS; APPARATUS THEREFOR
    • C25C1/00—Electrolytic production, recovery or refining of metals by electrolysis of solutions
    • C25C1/12—Electrolytic production, recovery or refining of metals by electrolysis of solutions of copper
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25C—PROCESSES FOR THE ELECTROLYTIC PRODUCTION, RECOVERY OR REFINING OF METALS; APPARATUS THEREFOR
    • C25C1/00—Electrolytic production, recovery or refining of metals by electrolysis of solutions
    • C25C1/20—Electrolytic production, recovery or refining of metals by electrolysis of solutions of noble metals
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25C—PROCESSES FOR THE ELECTROLYTIC PRODUCTION, RECOVERY OR REFINING OF METALS; APPARATUS THEREFOR
    • C25C5/00—Electrolytic production, recovery or refining of metal powders or porous metal masses
    • C25C5/02—Electrolytic production, recovery or refining of metal powders or porous metal masses from solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F2202/00—Treatment under specific physical conditions
    • B22F2202/11—Use of irradiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Nanotechnology (AREA)
  • Electrochemistry (AREA)
  • Mechanical Engineering (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980063142.3A 2018-09-26 2019-09-25 原子量子簇的治疗用途 Pending CN113179632A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510224683.7A CN120053481A (zh) 2018-09-26 2019-09-25 原子量子簇的治疗用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18196959 2018-09-26
EP18196963 2018-09-26
EP18196959.3 2018-09-26
EP18196963.5 2018-09-26
PCT/ES2019/070637 WO2020065115A2 (es) 2018-09-26 2019-09-25 Usos terapéuticos de clústeres cuánticos atómicos

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510224683.7A Division CN120053481A (zh) 2018-09-26 2019-09-25 原子量子簇的治疗用途

Publications (1)

Publication Number Publication Date
CN113179632A true CN113179632A (zh) 2021-07-27

Family

ID=68342935

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980063142.3A Pending CN113179632A (zh) 2018-09-26 2019-09-25 原子量子簇的治疗用途
CN202510224683.7A Pending CN120053481A (zh) 2018-09-26 2019-09-25 原子量子簇的治疗用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510224683.7A Pending CN120053481A (zh) 2018-09-26 2019-09-25 原子量子簇的治疗用途

Country Status (11)

Country Link
US (1) US20220031740A1 (https=)
EP (1) EP3862109A2 (https=)
JP (2) JP2022502450A (https=)
KR (1) KR20210086606A (https=)
CN (2) CN113179632A (https=)
AU (2) AU2019349780B2 (https=)
BR (1) BR112021005775A2 (https=)
CA (1) CA3111915A1 (https=)
IL (1) IL281663A (https=)
MX (1) MX2021003566A (https=)
WO (1) WO2020065115A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1303421C (zh) * 2004-03-24 2007-03-07 南京大学 一种用于有机氯、有机磷农药分析的同步净化提取方法
KR102927722B1 (ko) * 2020-05-09 2026-02-19 선전 프로파운드 뷰 파마슈티칼 테크놀로지 컴퍼니 리미티드 비정형 항정신병약물에 의해 유발되는 부작용의 치료
CN111906328B (zh) * 2020-08-11 2022-10-25 苏州大学 一种177Lu标记的金纳米团簇及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101113046A (zh) * 2006-07-25 2008-01-30 安正五 纳米胶体银水的制备方法
CN101248003A (zh) * 2005-08-03 2008-08-20 圣地亚哥联合大学 稳定的原子量子团簇及其生产方法和用途
CN101486733A (zh) * 2009-03-09 2009-07-22 华南师范大学 含氧桥双核钼原子簇化合物及其制备方法和用途
WO2012059572A1 (en) * 2010-11-05 2012-05-10 Universidade De Santiago De Compostela COMBINATION OF ATOMIC QUANTUM CLUSTERS (AQCs) AND ANTINEOPLASIC DRUGS, AND ITS USE IN THE PREVENTION AND/OR TREATMENT OF CELL PROLIFERATIVE DISORDERS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2319064B1 (es) * 2007-10-05 2010-02-15 Universidad De Santiago De Compostela Uso de clusteres cuanticos atomicos (aqcs) como antimicrobianos y biocidas.
WO2015015301A2 (en) * 2013-07-31 2015-02-05 Palama Ilaria El Cancer therapy with silver nanoparticles
KR20210021306A (ko) * 2018-06-12 2021-02-25 나노갭 서브-엔엠-파우더, 쏘시에다드 아노니마 정제된 원자 양자 클러스터를 제조하는 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101248003A (zh) * 2005-08-03 2008-08-20 圣地亚哥联合大学 稳定的原子量子团簇及其生产方法和用途
CN101113046A (zh) * 2006-07-25 2008-01-30 安正五 纳米胶体银水的制备方法
CN101486733A (zh) * 2009-03-09 2009-07-22 华南师范大学 含氧桥双核钼原子簇化合物及其制备方法和用途
WO2012059572A1 (en) * 2010-11-05 2012-05-10 Universidade De Santiago De Compostela COMBINATION OF ATOMIC QUANTUM CLUSTERS (AQCs) AND ANTINEOPLASIC DRUGS, AND ITS USE IN THE PREVENTION AND/OR TREATMENT OF CELL PROLIFERATIVE DISORDERS
EP2457572A1 (en) * 2010-11-05 2012-05-30 Universidade De Santiago De Compostela Use of atomic quantum clusters (aqcs) in the prevention of cell proliferative disorders, viral infections and autoimmune diseases

Also Published As

Publication number Publication date
MX2021003566A (es) 2021-08-16
AU2025238114A1 (en) 2025-10-23
WO2020065115A2 (es) 2020-04-02
BR112021005775A2 (pt) 2021-06-29
EP3862109A2 (en) 2021-08-11
AU2019349780A1 (en) 2021-03-25
WO2020065115A3 (es) 2020-05-22
US20220031740A1 (en) 2022-02-03
AU2019349780B2 (en) 2025-07-03
CA3111915A1 (en) 2020-04-02
JP2022502450A (ja) 2022-01-11
JP2024122998A (ja) 2024-09-10
CN120053481A (zh) 2025-05-30
IL281663A (en) 2021-05-31
KR20210086606A (ko) 2021-07-08

Similar Documents

Publication Publication Date Title
Narayana et al. Inorganic nanoparticle-based treatment approaches for colorectal cancer: recent advancements and challenges
JP2024122998A (ja) 原子量子クラスターの治療的使用
CN103608139B (zh) 表面改性的重金属纳米粒子、组合物及其用途
Akter et al. Gold nanoparticles in triple-negative breast cancer therapeutics
US10688125B2 (en) Nanoparticles and their use in cancer therapy
Arojojoye et al. Circumventing physicochemical barriers of cyclometalated gold (III) dithiocarbamate complexes with protein-based nanoparticle delivery to enhance anticancer activity
US10035806B2 (en) Derivatized corroles and metallocorroles and their use as imaging and therapeutic agents
US20240059719A1 (en) Gold complexes as anticancer agent
HK40057518A (en) Therapeutic uses of atomic quantum clusters
Wang et al. Repurposing antihistamine to chemotherapy via a molecular delivery platform co-targeting mitochondria and endoplasmic reticulum
US20260084978A1 (en) Process for producing atomic quantum clusters derivatives
Hu et al. Biomineralized Cu-Disulfiram nanoparticles Potentiate Colorectal cancer immunotherapy through synergistic cuproptosis and apoptosis
US20240009212A1 (en) Phosphaplatin compounds as therapeutic agents selectively targeting highly glycolytic tumor cells and methods thereof
Rangone Anticancer activity of multifunctional Pt (IV) prodrugs
Burney Marine Natural Products with Cytotoxic Properties against Epithelial Ovarian Cancer
WO2026036187A1 (en) Methods of treating cns cancers
WO2025193796A1 (en) Ros-activatable prodrugs of doxazolidine as novel cancer therapy paradigm
Baker Selective cancer therapies: targeting TRP channels in glioblastoma and prostate cancer
Krystof et al. Active p53 contributes to antitumor effects of cyclin-dependent kinase roscovitine in multiple myeloma cells
Huxham et al. 257 POSTER Tirapazamine disrupts vascular endothelial-cadherin, suggesting a mechanism behind its ability to cause central vascular dysfunction
Pasqualini et al. 254 INVITED Tumour vascular diversity and its translation into targeted therapeutics
Hart et al. 255 INVITED Targeting the invasio-association integrin alphavbeta6 as an anti-carcinoma strategy
Williams 256 INVITED Targeting hypoxia as an anti-metastatic strategy
Welch et al. 253 INVITED The KISS1 metastasis suppressor regulates tumor cell response to microenvironmental signals and growth at secondary sites

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination